Ancient herbal mix targets dual gut disorders in one shot
NCT ID NCT07715760
First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time
Summary
This study tests whether a traditional Chinese herbal formula called Hewei Anchang Formula can ease overlapping symptoms of functional dyspepsia (indigestion) and diarrhea-predominant irritable bowel syndrome (IBS-D). Researchers will give 120 adults either the herbal granules or a placebo for 4 weeks and track symptom changes. The goal is to see if one treatment can address both conditions at once, based on the idea that they share an underlying imbalance.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- a Chinese herbal formula called Hewei Anchang Formula, taken as granules dissolved in warm water
- What this could lead to
- If effective, this herbal formula could offer a new treatment option for people with both functional dyspepsia and diarrhea-predominant IBS, reducing overlapping symptoms.
- What could go wrong
- This is a small, early-stage trial with 120 participants, and the placebo contains a small amount of the active formula, which may affect results. The herbal mixture is complex, making it hard to pinpoint which ingredients work.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 120 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jan 2027
An estimate. Start dates often move.
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Meet the Rome IV diagnostic criteria for both functional dyspepsia (FD) and diarrhea-predominant irritable bowel syndrome (IBS-D). 2. Meet the diagnostic criteria for liver-stomach disharmony syndrome in FD and liver qi stagnation with spleen deficiency syndrome in IBS-D. 3. Aged 18-65 years, with no restriction on sex. 4. Fully informed about the study and voluntarily provide written informed consent. - Exclusion Criteria: 1. Severe primary diseases of the cardiovascular, hepatic, renal, hematologic, or respiratory systems, or malignant tumors. 2. Other organic gastrointestinal diseases, such as peptic ulcer or ulcerative colitis, or systemic diseases that may affect gastrointestinal motility, such as hyperthyroidism or diabetes mellitus. 3. Current or anticipated continuous use of medications that may affect gastrointestinal function, including prokinetic agents, antidiarrheal agents, antidepressants, anxiolytics, gut microbiota-modulating agents, and antibiotics. 4. A history of allergy to any study-related medication or a history of severe food allergy. 5. Psychiatric disorders, intellectual impairment, or language impairment. 6. Women who are planning pregnancy, pregnant, or breastfeeding. 7. Current participation in another drug clinical trial or participation in another drug clinical trial within the previous 4 weeks. 8. Severe anxiety or depression, as assessed using the Hospital Anxiety and Depression Scale (HADS). An anxiety subscale score of ≥15 is defined as severe anxiety, and a depression subscale score of ≥15 is defined as severe depression. Participants meeting the criterion for severe anxiety or severe depression on either subscale will be excluded. 9. A suspected or confirmed history of alcohol or drug abuse, or other circumstances that, in the investigator's judgment, may reduce the likelihood of enrollment or complicate study participation, such as frequent changes in the work environment that may increase the risk of loss to follow-up. -
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Functional dyspepsia are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Beijing, Beijing Municipality, 100091, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a nickel allergy explain your Child's stomach pain?
- Can a pudding snack reveal how the brain misreads the stomach?
- Beyond h. pylori: a hidden stomach bacteria may influence cancer risk
- Wheat sensitivity linked to fatty liver? a new study investigates
- Digestive health mystery: study seeks to uncover hidden burden of stomach pain in rural bangladesh
- New hope for chronic stomach pain: DA-9701 put to the test